# Cardiovascular Agents - Lipotropics 

|||
| ---------- | ---------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 1 | NP- HMG-CoA Reductase Inhibitors - Altoprev, Atorvaliq, Ezallor, Fluvastatin, Livalo, Zypitamag Amlodipine/Atorvastatin, Ezetimibe/Simvastatin |
| Criteria 2 | NP- Niacin Derivatives - Niacin ER Tab                                                                                                         |
| Criteria 3 | NP- Fibrates - Fenofibrate Cap, Fenofibrate 40, 54, 120, 160mg Tab, Fenofibric Acid                                                            |
| Criteria 4 | NP- ATP Citrate Lyase (ACL) Inhibitors - Nexletol, Nexlizet                                                                                    |
| Criteria 5 | NP- Bile Acid Sequestrants – Colesevelam, Colestipol Granules                                                                                  |
| Criteria 6 | NP- Juxtapid                                                                                                                                   |
| Criteria 7 | NP- Omega- 3 Fatty Acids- Vascepa, Icosapent Ethyl                                                                                             |
| Criteria 8 | P- PCSK-9 Inhibitors- Praluent (P, PA), Repatha (P, PA)                                                                                        |

 

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- HMG-CoA Reductase Inhibitors and Combination Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ALTOPREV</td>
<td>050556</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALTOPREV</td>
<td>050557</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ALTOPREV</td>
<td>050558</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ATORVALIQ</td>
<td>084377</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>EZALLOR</td>
<td>079379</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>EZALLOR</td>
<td>079380</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>EZALLOR</td>
<td>079381</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>EZALLOR</td>
<td>079382</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FLUVASTATIN</td>
<td>021694</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FLUVASTATIN</td>
<td>021695</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FLUVASTATIN</td>
<td>046757</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>LIVALO</td>
<td>066349</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>LIVALO</td>
<td>066350</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>LIVALO</td>
<td>066351</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ZYPITAMAG</td>
<td>077568</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ZYPITAMAG</td>
<td>077569</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053689</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053690</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053691</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053692</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053693</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053694</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053695</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>053696</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>058432</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>058433</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AMLODIPINE/ATORVASTATIN</td>
<td>058434</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>EZETIMIBE/SIMVASTATIN</td>
<td>057859</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>EZETIMIBE/SIMVASTATIN</td>
<td>057863</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>EZETIMIBE/SIMVASTATIN</td>
<td>057864</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>EZETIMIBE/SIMVASTATIN</td>
<td>057865</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0997</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td>Select</td>
<td>What product is being requested?</td>
<td>Altoprev</td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fluvastatin</td>
<td>1000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Livalo</td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with <span class="underline">two preferred</span> drugs in the same drug class?</p>
<p>The preferred product(s) are as follows: Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">one</span> <span class="underline">preferred</span> drug in the same drug class?</p>
<p>The preferred product(s) are as follows: Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1002</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td>Y    </td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>10</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>11</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- Niacin Derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>NIACIN ER TAB</td>
<td>033364</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>NIACIN ER TAB</td>
<td>033365</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>NIACIN ER TAB</td>
<td>033366</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="even">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="even">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">one preferred</span> drug in the same drug class?</p>
<p>The preferred product(s) are as follows: Niacin IR, Niacin ER OTC</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="even">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="even">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td> Y    </td>
<td>END (Approve x 365 days )</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- Fibrate Deriviatives- Fenofibrate Cap, Fenofibrate 40, 54, 120, 160mg Tab, Fenofibric Acid</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>063024</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>063025</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>043060</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>043061</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>044305</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>058479</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>058480</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>071642</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE CAP</td>
<td>071643</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE 40, 54, 120, 160 mg TAB</td>
<td>044915</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE 40, 54, 120, 160 mg TAB</td>
<td>063693</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRATE 40, 54, 120, 160 mg TAB</td>
<td>063694</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRATE 40, 54, 120, 160 mg TAB</td>
<td>064310</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FENOFIBRIC ACID</td>
<td>064676</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FENOFIBRIC ACID</td>
<td>064677</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">one preferred</span> drug in the same drug class?</p>
<p>The preferred product(s) are as follows: Fenofibrate 48mg Tab, Fenofibrate 145mg Tab, Gemfibrozil</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- ACL Inhibitors - Nexletol, Nexlizet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>NEXLETOL</td>
<td>080782</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>NEXLIZET</td>
<td>080790</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline labs <strong>AND</strong> documented adherence to <span class="underline">90 days</span> of prescribed lipid lowering medications?</td>
<td>Y</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> <strong>AND</strong> is unable to reach goal LDL-C with high-potency statin, ezetimibe, and PCSK9 inhibitor?</p>
<p>Please note:</p>
<ol type="1">
<li><p>High potency statins: atorvastatin 40-80mg &amp; rosuvastatin 20-40mg</p></li>
<li><p>LDL goals for <span class="underline">Familial Hypercholesterolemia</span> (FH) (includes Heterozygous &amp; Homozygous FH): LDL less than or equal to 100mg/dL for adults or LDL less than or equal to 110mg/dL for those less than 18 years of age.</p></li>
<li><p>LDL goals for Clinical Atherosclerotic Cardiovascular Disease (ASCVD): LDL less than or equal to 70mg/dL</p></li>
</ol>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Is there a clinical reason that these drugs (high-potency statin, ezetimibe and PCSK9 inhibitor) cannot be utilized?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td>Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>9</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial- 84 days; Subsequent- 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- Bile Acid Sequestrants - Colesevelam, Colestipol Granules</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>COLESEVELAM</td>
<td>046172</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>COLESTIPOL GRANULES</td>
<td>003101</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>COLESTIPOL GRANULES</td>
<td>003102</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>COLESTIPOL GRANULES</td>
<td>021429</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">one preferred</span> drug in the same drug class?</p>
<p>The preferred product(s) are as follows: Cholestyramine Regular, Cholestyramine Light, Colestipol Tab, Prevalite</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>What product is being requested?</td>
<td>Colesevelam</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colestipol Granules</td>
<td>1004</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of a Type 2 Diabetes diagnosis?</td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>9</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td>Y    </td>
<td>END (Approve x 365 days) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>10</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>11</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Juxtapid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>JUXTAPID</td>
<td>070393</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>JUXTAPID</td>
<td>070394</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>JUXTAPID</td>
<td>070395</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>JUXTAPID</td>
<td>074053</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>JUXTAPID</td>
<td>074054</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>JUXTAPID</td>
<td>074055</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline labs <strong>AND</strong> documented adherence to <span class="underline">90 days</span> of prescribed lipid lowering medications?</td>
<td>Y</td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> <strong>AND</strong> is unable to reach goal LDL-C with high-potency statin, ezetimibe, and PCSK9 inhibitor?</p>
<p>Please note:</p>
<ol type="1">
<li><p>High potency statins: atorvastatin 40-80mg &amp; rosuvastatin 20-40mg</p></li>
<li><p>LDL goals for <span class="underline">Familial Hypercholesterolemia</span> (FH) (includes Heterozygous &amp; Homozygous FH): LDL less than or equal to 100mg/dL for adults or LDL less than or equal to 110mg/dL for those less than 18 years of age.</p></li>
<li><p>LDL goals for Clinical Atherosclerotic Cardiovascular Disease (ASCVD): LDL less than or equal to 70mg/dL</p></li>
</ol>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Is there a clinical reason that these drugs (high-potency statin, ezetimibe and PCSK9 inhibitor) cannot be utilized?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>9</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>10</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial- 180 days; Subsequent- 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred- Omega-3 Fatty Acids Vascepa, Icosapent Ethyl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ICOSAPENT ETHYL</td>
<td>069960</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ICOSAPENT ETHYL</td>
<td>076660</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>VASCEPA</td>
<td>069960</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>VASCEPA</td>
<td>076660</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">one preferred</span> drug in the same drug class?</p>
<p>The preferred product(s) are as follows: Omega-3-Acid Ethyl Esters</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td>What product is being requested?</td>
<td>Brand Vascepa</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Generic icosapent ethyl</td>
<td>1003</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>1235</td>
</tr>
<tr class="even">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the brand medication been attempted and failed or is the brand medication contraindicated?  </p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline labs indicating triglyceride levels greater than or equal to 500mg/dL after an inadequate clinical response to fibrates, niacin, and diet/exercise?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of discontinuation of drugs known to increase triglyceride levels (i.e., beta blockers, thiazides, and estrogens), if clinically appropriate?</td>
<td>Y</td>
<td>1006</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>11</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>12</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>13</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial- 84 days; Subsequent- 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Cardiovascular Agents: Lipotropics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Preferred- PCSK-9 Inhibitors - Praluent (P, PA), Repatha (P, PA) </td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>PRALUENT</td>
<td>074511</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>PRALUENT</td>
<td>074513</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>REPATHA</td>
<td>074564</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REPATHA</td>
<td>074663</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>REPATHA</td>
<td>076353</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of baseline labs <strong>AND</strong> documented adherence to <span class="underline">90 days</span> of prescribed lipid lowering medications?</td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> <strong>AND</strong> is unable to reach goal LDL-C despite treatment with maximally tolerated dose of high-potency statin and ezetimibe?</p>
<p>Please note:</p>
<ol type="1">
<li><p>High potency statins: atorvastatin 40-80mg &amp; rosuvastatin 20-40mg</p></li>
<li><p>LDL goals for <span class="underline">Familial Hypercholesterolemia</span> (FH) (includes Heterozygous &amp; Homozygous FH): LDL less than or equal to 100mg/dL for adults or LDL less than or equal to 110mg/dL for those less than 18 years of age.</p></li>
<li><p>LDL goals for Clinical Atherosclerotic Cardiovascular Disease (ASCVD): LDL less than or equal to 70mg/dL</p></li>
</ol>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1002</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Is there a clinical reason that these drugs (high-potency statin, ezetimibe) cannot be utilized?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td>Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>7</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |
